Direct, sequence-perfect clonal DNA up to 50 kb is empowering customers to expand their design space and innovate without compromise.
Seasoned DNA synthesis executive will oversee expansion of production capacity to meet rising demand for high-quality long and complex DNA products backed by industry’s only service guarantee.
New collaboration empowers customers with sequence-perfect constructs as long as 50 kb.
Mr. Hamilton will lead the company’s financial operations, corporate strategy, and key partnerships as Ansa accelerates its commercial expansion across the biotechnology, synthetic biology, and pharmaceutical sectors.
Ansa is the first to deliver ultra-long, fully verified DNA in less than 25 days, backed by the industry’s only on-time guarantee. View the press release.
Ansa Biotechnologies, Inc. today announced that it has closed $45.2 million and secured commitments for an additional $9.2 million as part of an oversubscribed series B financing round. View the press release.
Ansa Biotechnologies, Inc., the trusted partner for DNA synthesis, today announced the launch of its 50 kb DNA synthesis early access program, providing customers with extremely long and complex DNA sequences in less than four weeks.
Combining its complex DNA synthesis platform with a unique long-read sequencing and analysis approach for quality control allows Ansa to produce long, complex DNA more accurately and reliably than any other DNA synthesis vendor. View the press release.
Ansa Biotechnologies announced the commercial availability of its Ansa Clonal DNA and Ansa DNA Fragments. Ansa is the only company able to synthesize complete, contiguous DNA oligonucleotides as long as 600 bp without requiring assembly, delivering products as sequence-perfect clonal DNA or sequence-verified linear double-stranded DNA fragments. View the press release.
Ansa Biotechnologies is expanding its early access program for its complex DNA synthesis services. More customers around the world will now be able to take advantage of the company’s innovative enzymatic DNA synthesis technology to accelerate innovation in healthcare, life science research, and other industries powered by synthetic DNA. View the press release.